[go: up one dir, main page]

AU2009257174A1 - Novel receptor hetero-dimers/-oligomers - Google Patents

Novel receptor hetero-dimers/-oligomers Download PDF

Info

Publication number
AU2009257174A1
AU2009257174A1 AU2009257174A AU2009257174A AU2009257174A1 AU 2009257174 A1 AU2009257174 A1 AU 2009257174A1 AU 2009257174 A AU2009257174 A AU 2009257174A AU 2009257174 A AU2009257174 A AU 2009257174A AU 2009257174 A1 AU2009257174 A1 AU 2009257174A1
Authority
AU
Australia
Prior art keywords
receptor
vasopressin
angiotensin
test compound
hetero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009257174A
Other languages
English (en)
Inventor
Matthew Blake Dalrymple
Elizabeth Mccall
Kevin Pfleger
Heng Boon See
Ruth Marie Seeber
James Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimerix Bioscience Pty Ltd
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008902974A external-priority patent/AU2008902974A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Priority to AU2009257174A priority Critical patent/AU2009257174A1/en
Publication of AU2009257174A1 publication Critical patent/AU2009257174A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2009257174A 2008-06-09 2009-06-09 Novel receptor hetero-dimers/-oligomers Abandoned AU2009257174A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009257174A AU2009257174A1 (en) 2008-06-09 2009-06-09 Novel receptor hetero-dimers/-oligomers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2008902974 2008-06-09
AU2008902974A AU2008902974A0 (en) 2008-06-09 Novel receptor hetero-dimers/-oligomers
AU2009257174A AU2009257174A1 (en) 2008-06-09 2009-06-09 Novel receptor hetero-dimers/-oligomers
PCT/AU2009/000720 WO2009149493A1 (fr) 2008-06-09 2009-06-09 Nouveaux récepteurs hétérodimères/hétéro-oligomères

Publications (1)

Publication Number Publication Date
AU2009257174A1 true AU2009257174A1 (en) 2009-12-17

Family

ID=41416271

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009257174A Abandoned AU2009257174A1 (en) 2008-06-09 2009-06-09 Novel receptor hetero-dimers/-oligomers

Country Status (2)

Country Link
AU (1) AU2009257174A1 (fr)
WO (1) WO2009149493A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US7417038B1 (en) * 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
ATE367815T1 (de) * 2000-10-04 2007-08-15 Astellas Pharma Inc Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
ES2533007T3 (es) * 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzoacepina soluble en agua y su composición farmacéutica

Also Published As

Publication number Publication date
WO2009149493A1 (fr) 2009-12-17

Similar Documents

Publication Publication Date Title
US12083102B2 (en) Method for treating inflammatory disorders
US20100234417A1 (en) Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
Danser The role of the (pro) renin receptor in hypertensive disease
US20120208843A1 (en) Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds
Wagenaar et al. Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats
Zhang et al. Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
KR20220070435A (ko) 질환의 치료를 위한 방법 및 조성물
AU2009257174A1 (en) Novel receptor hetero-dimers/-oligomers
US7611832B2 (en) Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
CA3139912A1 (fr) Inhibiteurs d'heteromeres de gpcr et leurs utilisations
US20120100130A1 (en) Novel Receptor Hetero-Dimers/-Oligomers
Dominici et al. Therapeutic opportunities in targeting the protective arm of the renin-angiotensin system to improve insulin sensitivity: a mechanistic review
WO2010003170A1 (fr) Nouveaux hétérodimères/hétéro-oligomères récepteurs
WO2014153044A1 (fr) Traitement de patients atteints d'une hyponatrémie et d'une maladie cardiaque
WO2010031114A1 (fr) Nouveaux récepteurs hétérodimères/-oligomères
WO2010129987A1 (fr) Nouveaux hétérodimères/hétéro-oligomères récepteurs
ES2770785T3 (es) Terapia de combinación
Lunder et al. Peptide mimetic of N‐terminal ghrelin enhances ghrelin‐induced growth hormone secretion and c‐Fos expression in mice
Grämer Development of a GRK2-inhibitory peptide
HK1192712B (en) Combination therapy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period